Search for: "In re Clovis Oncology, Inc. Derivative Litigation"
Results 1 - 14
of 14
Sorted by Relevance
|
Sort by Date
14 Oct 2019, 5:47 am
On October 1, the Delaware Court of Chancery denied a motion to dismiss a Caremark claim in In re Clovis Oncology, Inc. [read post]
11 Oct 2019, 6:00 am
In Re Clovis Oncology, Inc. [read post]
5 Oct 2019, 7:03 am
In re Clovis Oncology, Inc. [read post]
7 Oct 2019, 10:59 am
In the latest example, the court held that, for purposes of a motion to dismiss, a shareholder derivative complaint sufficiently pleaded that Clovis Oncology, Inc. [read post]
15 Oct 2019, 3:00 pm
Sources: In re Clovis Oncology, Inc. [read post]
16 Oct 2019, 10:59 am
The business judgment rule cannot shield Clovis Oncology Inc. [read post]
27 May 2020, 5:19 am
Hughes is now the second decision, after In re Clovis Oncology, Inc. [read post]
15 Feb 2023, 9:05 pm
Barnhill, 212 A.3d 822 (2018). [2] See PWC 2021 Annual Corporate Directors Survey, The Director’s New Playbook: Taking on Change, at 6. [3] See In re Caremark Inc Derivative Litigation, 698 A.2d 959, 970 (Del. [read post]
16 Mar 2020, 1:54 pm
An early example of Lorenzo having an impact (albeit short-lived) in private litigation is In re Longfin Corp Sec. [read post]
25 May 2022, 9:01 pm
Compare In re NVIDIA Corp. [read post]
20 Jan 2021, 2:21 pm
Derivative Litigation. [read post]
6 Apr 2020, 1:40 pm
Barnhill and In re Clovis Oncology, Inc. [read post]
23 Mar 2020, 1:48 pm
D&O underwriters cannot – and do not – expect that the public company risks they underwrite will never experience a D&O claim, and especially a shareholder class action or derivative claim. [read post]
4 Jan 2021, 1:26 pm
If the merger objection lawsuits are disregarded, the litigation rate translates to about 4.7%, which although below the record-level litigation rates during the period 2017 -2019 is still well above the 1996-2018 annual litigation rate of 3.0%. [read post]
